Repeated mismatches may not impair survival of renal regrafts in recipients with 0% to 50% panel reactive antibodies.
Mjörnstedt
L
L
Department of Surgery (Transplant Unit), Sahlgrenska Hospital, Göteborg, Sweden.
Konar
J
J
Skarp
I
I
Olausson
M
M
Sandberg
L
L
Tufvesson
G
G
D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology; D015235:HLA-B Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007518:Isoantibodies / Q000032:analysis*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D011183:Postoperative Complications / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D012086:Reoperation; D012307:Risk Factors; D015996:Survival Rate
D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D007518:Isoantibodies